MoonLake Immunotherapeutics (MLTX) Change in Acquisitions & Divestments (2022 - 2026)

MoonLake Immunotherapeutics' Change in Acquisitions & Divestments history runs 5 years deep, the most recent figure standing at $59.2 million for Q1 2026.

• In Q1 2026, Change in Acquisitions & Divestments fell 59.15% year-over-year to $59.2 million; the TTM figure through Mar 2026 stood at $382.7 million (up 65.75% YoY), while the FY2025 annual figure was $468.4 million, up 222.58% from the prior year.
• Change in Acquisitions & Divestments was $59.2 million for Q1 2026 at MoonLake Immunotherapeutics, up from $29.3 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $205.9 million in Q2 2025 to a low of -$1.3 million in Q2 2024.
• Historically, Change in Acquisitions & Divestments has averaged $59.5 million across 5 years, with a median of $44.2 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Change in Acquisitions & Divestments tumbled 110.26% in 2024, then surged 15927.29% in 2025.
• A 5-year view of Change in Acquisitions & Divestments shows it stood at $9.9 million in 2022, then surged by 1083.17% to $117.2 million in 2023, then tumbled by 100.18% to -$211000.0 in 2024, then surged by 13965.4% to $29.3 million in 2025, then surged by 102.24% to $59.2 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $59.2 million (Q1 2026), $29.3 million (Q4 2025), and $88.4 million (Q3 2025), per Business Quant data.